The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen planus with oral upadacitinib, and many more. Straight from the Editor’s desk, check out this month’s issue highlights.
A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis examines promising, emerging treatments that shows clinical improvement and fewer adverse effects in case studies.
Onychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016 underscores the need for greater awareness and education about onychomycosis therapy, emphasizing the crucial role of dermatologists in its management.
The Association Between Herpes Simplex Virus and Alzheimer’s Disease: A Systematic Review analyzes their potential connection and raises the possibility of using anti-viral medications to mitigate AD.
Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade reviews five different clinical effects and their supporting evidence.
Cidofovir in the Management of Non-Genital Warts: A Review discusses how this topical treatment may serve as an effective, safe, and affordable alternative for the clearance of recalcitrant non-genital warts.
Ant Venom-Based Ceramide Therapy is Effective Against Atopic Dermatitis In Vivo discusses the unmet need for novel therapies for AD and offers insight into an innovative treatment.
Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis indicates that one continuous treatment approach yielded significantly higher clinical cure rates in managing this common condition.
A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development discusses the surge in drug development offering the prospect of improved HS management and better quality of life for patients in the coming years.
Selection Of Nemolizumab Clinical Dosage for Atopic Dermatitis explores how this treatment shows great potential in alleviating the suffering of patients with atopic dermatitis (AD).
Keratosis Pilaris: Treatment Practices of Board-Certified Dermatologists sheds light on the current practices and perceptions within the dermatology community.
Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases delves into treatment efficacy, particularly for non-responsive cases, and its potential impact on mental health and quality of life.
The Psychosocial Burden of Skin Disease and Dermatology Care Insights Among Skin of Color Consumers highlights the urgent need for tailored dermatological solutions and education to address the unique challenges faced by SoC individuals.
Post-Hoc Exploratory Pooled Analysis of the Impact of IDP-126 Gel on QoL in Moderate-to-Severe Acne discusses the profound impact of IDP-126 Gel on the lives of individuals dealing with this condition.
Successful Treatment of Lichen Planus With Oral Upadacitinib explores an emerging treatment as a potential game-changer for those seeking relief from refractory lichen planus.
Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic spotlights how dermatologists play a crucial role in the fight against antimicrobial resistance and microbiome dysbiosis.
Topical Ivermectin is Associated With Improved Erythematotelangiectatic, Papulopustular, and Phymatous Rosacea in a Secondary Analysis suggests that IVM may target the underlying causes of rosacea, not just the papulopustular type.
Participant Satisfaction of a Community-based Telehealth Clinic for Atopic Dermatitis describes how strategically located telemedicine clinics combining education and care can significantly enhance AD patient outcomes.
Updates in the Treatment of Body-Focused Repetitive Disorders reinforces how dermatologists play a crucial role in recognizing BFRBs, which often show skin-related signs or may be triggered by dermatologic issues.
Find more JDD Issue Highlights here.